<DOC>
	<DOCNO>NCT01535053</DOCNO>
	<brief_summary>This randomized phase III trial study well methotrexate work compare dactinomycin treat patient low-risk gestational trophoblastic neoplasia . Drugs use chemotherapy , methotrexate dactinomycin , work different way stop growth tumor cell , either kill cell , stop dividing , stop spread . It yet know whether methotrexate effective dactinomycin treat gestational trophoblastic disease .</brief_summary>
	<brief_title>Dactinomycin Methotrexate Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To test hypothesis treatment multi-day methotrexate inferior treatment pulse actinomycin-D ( dactinomycin ) patient low-risk gestational trophoblastic disease respect complete response . SECONDARY OBJECTIVES : I . To describe frequency post protocol surgical treatment arm . II . To describe frequency post protocol multi-agent chemotherapy treatment arm . III . To compare multi-day methotrexate actinomycin-D respect frequency severity adverse event patient low-risk gestational trophoblastic neoplasia . IV . To investigate impact treatment overall quality-of-life ( QOL ) explore influence treatment issue body image , sexual functioning , patient-reported side effect disruption . V. To assess whether uterine artery pulsatility index ( UAPI ) provide independent prognostic information predictive single-drug resistance . OUTLINE : Patients randomize 1 2 treatment arm . ARM I : Patients receive dactinomycin intravenously ( IV ) 15 minute day 1 . ARM II : Patients receive methotrexate intramuscularly ( IM ) day 1 , 3 , 5 , 7 leucovorin calcium orally ( PO ) day 2 , 4 , 6 , 8 OR single agent methotrexate IV day 1-5 . In arm , treatment repeat every 14 day 20 courses* absence disease progression unacceptable toxicity . After completion study treatment , patient follow monthly 1 year every 3 month 1 year . NOTE : * Patients treat three course human chorionic gonadotropin ( hCG ) &lt; 5 mIU/mL evidence treatment failure ( biologic progression ) , disease progression , unacceptable toxicity despite dose modification . Upon normalization hCG ( &lt; 5 mIU/mL ) , patient treat three additional course .</detailed_description>
	<mesh_term>Choriocarcinoma</mesh_term>
	<mesh_term>Trophoblastic Neoplasms</mesh_term>
	<mesh_term>Gestational Trophoblastic Disease</mesh_term>
	<mesh_term>Hydatidiform Mole</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Dactinomycin</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<criteria>Patients meet International Federation Gynecology Obstetrics ( FIGO ) stage I , II , III criterion lowrisk gestational trophoblastic neoplasia ( GTN ) : post molar GTN choriocarcinoma ( define ) ; patient may second curettage must still meet GTN criterion : Post molar GTN For purpose study , patient must undergo evacuation complete partial hydatidiform mole meet criterion GTN define : A &lt; 10 % decrease hCG level use reference first value series 4 value take period 3 week ( &gt; 50 mIU/ml minimum ) OR A &gt; 20 % sustain rise hCG take reference first value series 3 value take period 2 week ( &gt; 50 mIU/ml minimum ) OR A persistently elevate hCG level period 6 month follow initial curettage ( &gt; 50 mIU/ml minimum ) Choriocarcinoma Histologically proven nonmetastatic choriocarcinoma OR Histologically proven metastatic choriocarcinoma metastatic site ( ) restrict one ( ) following : vagina , parametrium , lung World Health Organization ( WHO ) risk score 06 Patients must willing practice effective contraception duration study White blood cell count ( WBC ) &gt; = 3,000 cells/mcL Granulocytes &gt; = 1,500/mcL Platelets &gt; = 100,000/mcL Creatinine = &lt; 2.0 mg/dcL Bilirubin = &lt; 1.5 x institutional normal Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) = &lt; 3 x institutional normal Alkaline phosphatase = &lt; 3 x institutional normal Patients meet preentry requirement Before enrol patient , institution must verify availability adequate supply methotrexate full course therapy Patients must sign approve informed consent authorization permit release personal health information Patients GTN Patients nongestational choriocarcinoma Patients previously treat cytotoxic chemotherapy ; however , patient receive prior lowdose methotrexate treatment ectopic pregnancy eligible study Patients receive prior pelvic radiation Patients placentalsite trophoblastic tumor ( PSTT ) epithelioid trophoblastic tumor ( ETT ) Patients Gynecologic Oncology Group ( GOG ) performance status 3 4 Patients history invasive malignancy , exception nonmelanoma skin cancer , exclude evidence malignancy present within last five year ; patient also exclude previous cancer treatment contraindicate protocol therapy Patients whose circumstance time study entry permit completion study require followup Patients wish breastfeed treatment</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>